Can Pletal (cilostazol) cause peripheral edema in the legs?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Pletal Cause Leg Swelling?

Yes, Pletal (cilostazol) can cause peripheral edema (leg swelling), though it occurs less frequently than other common side effects like headache and diarrhea.

Evidence from FDA Drug Label

According to the FDA-approved prescribing information, peripheral edema occurred in 9% of patients taking cilostazol 50 mg twice daily and 7% of patients taking 100 mg twice daily, compared to 4% in the placebo group 1. This represents a modest but measurable increase in leg swelling compared to placebo.

Clinical Context and Mechanism

The peripheral edema associated with cilostazol is likely related to its vasodilatory properties. As a phosphodiesterase III inhibitor, cilostazol causes vasodilation of peripheral arteries 2, 3. This vasodilatory effect can lead to fluid accumulation in the lower extremities through increased hydrostatic pressure in the capillaries 4, 5.

Relative Frequency Among Side Effects

While peripheral edema does occur with cilostazol, it is not among the most common adverse effects. The most frequently reported side effects according to the 2024 ACC/AHA guidelines and FDA labeling include 6, 1:

  • Headache (27-34% of patients)
  • Diarrhea (12-19% of patients)
  • Abnormal stools (12-15% of patients)
  • Dizziness (9-10% of patients)
  • Palpitations (5-10% of patients)

Peripheral edema ranks lower in frequency but is still clinically relevant.

Important Clinical Considerations

Contraindication in Heart Failure

Cilostazol is absolutely contraindicated in patients with congestive heart failure of any severity 6, 1. This is critical because:

  • Other phosphodiesterase III inhibitors (like milrinone) have shown excess mortality in heart failure patients
  • If a patient develops leg swelling while on cilostazol, you must distinguish between drug-induced peripheral edema and new or worsening heart failure
  • Symptoms of heart failure include shortness of breath and leg swelling, which could be confused with cilostazol's side effects

Monitoring Recommendations

When prescribing cilostazol 6:

  • Assess patient tolerance at 2 to 4 weeks
  • Evaluate clinical benefit within 3 to 6 months
  • If peripheral edema develops, evaluate for heart failure before continuing therapy
  • Consider discontinuation if no benefit is seen after 12 weeks

Management Approach

If leg swelling develops in a patient taking cilostazol:

  1. Rule out heart failure immediately - This is the priority given the contraindication
  2. Assess severity - Mild edema may be tolerable if claudication symptoms are improving significantly
  3. Consider dose reduction - Though not specifically studied for edema, reducing from 100 mg to 50 mg twice daily may help
  4. Weigh risk-benefit - Balance the edema against improvement in walking distance and quality of life
  5. Consider discontinuation - If edema is bothersome or if heart failure cannot be excluded

The 2024 ACC/AHA guidelines note that approximately 20% of patients discontinue cilostazol within 3 months due to adverse effects, though headache and diarrhea are more common reasons than peripheral edema 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.